My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Anales del Sistema Sanitario de Navarra
Print version ISSN 1137-6627
Abstract
PEREZ DIEZ, C.; NAVARRO AZNAREZ, H. and LOU ARNAL, L.M.. Adherence to treatment with erythropoiesis stimulating agents. Anales Sis San Navarra [online]. 2020, vol.43, n.1, pp.81-85. Epub Aug 17, 2020. ISSN 1137-6627. https://dx.doi.org/10.23938/assn.0858.
Background
To establish adherence to treatment with erythropoiesis stimulating agents (ESA) in patients with anemia associated to chronic kidney disease (CKD), and analyze its relationship to response to ESA.
Methods
Retrospective study of a cohort of 198 patients with CKD who started treatment with epoetin-β or darbepoetin-α, followed for two years. Basal characteristics, effectiveness (% of hemoglobin (Hb) target attainment, percentage increase of Hb) and adherence (medication possession rate) were registered. A non-adherent patient was one whose mean adherence was <90%.
Results
Average global adhesion was 89.6%, slightly higher in treatment with darbepoetin-α than with epoetin-β; 8.6% of patients were non-adherents. Hb target was accomplished in 87% cases. Level of response to ESA treatment was independent of the degree of adherence to treatment.
Conclusions
Adherence to ESA treatment was good, without differences related to degree of response.
Keywords : Anemia; Chronic kidney failure; Therapeutic adherence; Erythropoietin; Epoetin alfa.
